The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

Metformin is a widely used antidiabetic agent, which regulates glucose homeostasis through inhibition of liver glucose production and an increase in muscle glucose uptake. Recent studies suggest that metformin may reduce the risk of cancer, but its mode of action in cancer remains not elucidated. We investigated the effect of metformin on human prostate cancer cell proliferation in vitro and in vivo. Metformin inhibited the proliferation of DU145, PC-3 and LNCaP cancer cells with a 50% decrease of cell viability and had a modest effect on normal prostate epithelial cell line P69. Metformin did not induce apoptosis but blocked cell cycle in G0/G1. This blockade was accompanied by a strong decrease of cyclin D1 protein level, pRb phosphorylation and an increase in p27kip protein expression. Metformin activated the AMP kinase pathway, a fuel sensor signaling pathway. However, inhibition of the AMPK pathway using siRNA against the two catalytic subunits of AMPK did not prevent the antiproliferative effect of metformin in prostate cancer cells. Importantly, oral and intraperitoneal treatment with metformin led to a 50 and 35% reduction of tumor growth, respectively, in mice bearing xenografts of LNCaP. Similar, to the in vitro study, metformin led to a strong reduction of cyclin D1 protein level in tumors providing evidence for a mechanism that may contribute to the antineoplastic effects of metformin suggested by recent epidemiological studies.

[1]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[2]  Young Ho Suh,et al.  AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. , 2007, Cellular signalling.

[3]  Y. Kloog,et al.  Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. , 2006, Biochemical pharmacology.

[4]  Campbell Iw.  Metformin and the sulphonylureas: the comparative risk. , 1985 .

[5]  Y. Le Marchand-Brustel,et al.  Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. , 2006, Diabetes.

[6]  D. Tindall,et al.  Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line , 1998, The Prostate.

[7]  O. Potapova,et al.  The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells , 1999, Molecular and Cellular Biology.

[8]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[9]  T. Hunter.  Oncoprotein Networks , 1997, Cell.

[10]  Stephanie Daignault,et al.  Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. , 2006, Cancer research.

[11]  D. Dunger,et al.  Metformin treatment to prevent early puberty in girls with precocious pubarche. , 2006, The Journal of clinical endocrinology and metabolism.

[12]  Chuan-ju Liu,et al.  IFI16 inhibits tumorigenicity and cell proliferation of bone and cartilage tumor cells. , 2007, Frontiers in bioscience : a journal and virtual library.

[13]  O. Potapova,et al.  Antisense methods for discrimination of phenotypic properties of closely related gene products: Jun kinase family. , 2000, Methods in enzymology.

[14]  Marco Zoli,et al.  Metformin in non-alcoholic steatohepatitis , 2001, The Lancet.

[15]  D. Hardie,et al.  AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. , 2005, Cell metabolism.

[16]  P. Auberger,et al.  Evidence for a p23 caspase-cleaved form of p27[KIP1] involved in G1 growth arrest , 1999, Oncogene.

[17]  B. Viollet,et al.  5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. , 2006, Diabetes.

[18]  James M. Roberts,et al.  Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.

[19]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[20]  D. Hardie,et al.  The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. , 2002, Diabetes.

[21]  S. Shurtleff,et al.  D-type cyclin-dependent kinase activity in mammalian cells , 1994, Molecular and cellular biology.

[22]  M. Prentki,et al.  AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. , 2003, Acta physiologica Scandinavica.

[23]  J. Isaacs,et al.  Development of prostate cancer treatment: The good news , 2004, The Prostate.

[24]  M. Rubin,et al.  Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors , 1998, The Prostate.

[25]  C. Tepper,et al.  E2F1 expression in LNCaP prostate cancer cells deregulates androgen dependent growth, suppresses differentiation, and enhances apoptosis , 2006, The Prostate.

[26]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[27]  T. Pulinilkunnil,et al.  Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3 , 2006, Diabetologia.

[28]  X. Leverve,et al.  Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. , 2005, Diabetes.

[29]  Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis , 2006, Molecular Cancer Therapeutics.

[30]  P. Auberger,et al.  Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis , 2004, Oncogene.

[31]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[32]  E. Berry,et al.  AMPK activation regulates apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes. , 2006, Biochemical and biophysical research communications.

[33]  J. Thrasher,et al.  The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. , 1996, The Journal of clinical endocrinology and metabolism.

[34]  LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. , 2000 .

[35]  R. Norman,et al.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.

[36]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[37]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[38]  C. Cordon-Cardo,et al.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[40]  X. Ding,et al.  Prevention of pancreatic cancer induction in hamsters by metformin. , 2001, Gastroenterology.

[41]  C. Conti,et al.  Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1 , 1998, Oncogene.

[42]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.